tasimelteon · Hetlioz
Small molecule
Evidence outlook
Approved: Non-24-Hour Sleep-Wake Disorder
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (2)
- Nighttime Sleep Disturbances in Smith-Magenis Syndrome (SMS) HETLIOZ capsules are indicated for the treatment of nighttime sleep disturbances in SMS in patients 16 years of age and older. HETLIOZ LQ oral suspension is indicated for the treatment of nighttime sleep disturbances in SMS in pediatric patients 3 to 15 years of age.
- Non-24-Hour Sleep-Wake Disorder in totally blind adults
Company guidance: data expected in 2026 (Vanda Pharmaceuticals, 6 Aug 2026). “◦ The Phase III study of HETLIOZ ® in the treatment of delayed sleep phase disorder (DSPD) with results expected in 2026.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01429116 NCT01429116 · Non-24-Hour Sleep-Wake Disorder Registry: NCT01429116 | 3 | Number of participants with Treatment-Emergent Adverse Events (AEs) (24 months + 12 month optional extension) 2015-01 | Results not posted; external-source review pending | not yet graded | link ↗ |
View 3 more trials
NCT01218789 NCT01218789 · Non-24-Hour Sleep-Wake Disorder Registry: NCT01218789 | 3 | Safety Evaluations (Week 4); Safety Evaluations (Week 8); Safety Evaluations (Week 12); Safety Evaluations (Week 16); Safety Evaluations (Week 26); Safety Evaluations (Week 34); Safety Evaluations (Week 42); Safety Evaluations (Week 52) 2024-12-05 | Results not posted; external-source review pending | not yet graded | link ↗ |
NCT01163032 NCT01163032 · Non-24-Hour Sleep-Wake Disorder Registry: NCT01163032 | 3 | Proportion of Patients Entrained as Assessed by Urinary aMT6 (1 month); Proportion of Patients With a Clinical Response: Entrainment of aMT6 and Score of ≥ 3 on N24CRS (6 months) 2012-11 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
NCT01430754 NCT01430754 · Non-24-Hour Sleep-Wake Disorder This was a randomized, quadruple-blind, placebo-controlled withdrawal trial, and continuing tasimelteon kept far more patients entrained than switching to placebo (9 of 10 vs 2 of 10, p=0.0026). The evidence is rated below the top level because only 20 patients were randomized and no power calculation or planned enrolment was found in the sources checked. Registry: NCT01430754 | 3 | Maintenance of Entrainment (aMT6s) in Subjects With N24HSWD. (Approximately 12 weeks) 2012-12 | RESET randomized withdrawal: maintenance of entrainment, continued tasimelteon vs withdrawal to placebo: 9/10 (90%) vs 2/10 (20%), difference 70% (95% CI 26.4 to 100.0), p=0.0026 (Lockley et al., Lancet 2015). | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Competitive landscape
Other Melatonin receptor (MT1/MT2) drugs
Melatonin prolonged-release. Compare all 2 Melatonin receptor (MT1/MT2) drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Tasimelteon (Hetlioz): this drug | Approved | Small molecule | Melatonin receptor (MT1/MT2) | Partial signal | NCT01430754: RESET randomized withdrawal: maintenance of entrainment, continued tasimelteon vs withdrawal to placebo: 9/10 (90%) vs 2/10 (20%), difference 70% (95% CI 26.4 to 100.0), p=0.0026 (Lockley et al., Lancet 2015). | |
| Melatonin Prolonged-Release (Circadin) | Phase 3(overall) | — | Melatonin receptor (MT1/MT2) | not yet graded | NCT01906866: Total Sleep Time (TST) (13 weeks): Circadin 2/5/10 mg 51.03 minutes (95% CI 30.3 to 71.76) vs Placebo 18.71 minutes (95% CI -2.73 to 40.15) |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Hetlioz (tasimelteon) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
November 2027 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent